

1 Understanding the impact of disease and vaccine mechanisms on the importance 2 of optimal vaccine allocation*

3 Isobel R. Abell^{1, 2}, James M. McCaw^{1, 3, 4}, and Christopher M. Baker^{1, 2, 5}

4 ¹School of Mathematics and Statistics, The University of Melbourne, Melbourne, Australia

5 ²Melbourne Centre for Data Science, The University of Melbourne, Melbourne, Australia

6 ³Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The
7 University of Melbourne, Melbourne, Australia

8 ⁴Peter Doherty Institute for Infection and Immunity, The Royal Melbourne Hospital and The
9 University of Melbourne, Australia

10 ⁵Centre of Excellence for Biosecurity Risk Analysis, The University of Melbourne, Melbourne,
11 Australia

12

13 **Abstract.** Vaccination is an important epidemic intervention strategy. Resource limitations and an imperative
14 for efficient use of public resources drives a need for optimal allocation of vaccines within a popula-
15 tion. For a disease causing severe illness in particular members of a population, an effective strategy
16 to reduce illness might be to vaccinate those vulnerable with a vaccine that reduces the chance of
17 catching a disease. However, it is not clear that this is the best strategy, and it is generally unclear
18 how the difference between various vaccine strategies changes depending on population characteris-
19 tics, vaccine mechanisms and allocation objective. In this paper we develop a mathematical model to
20 consider strategies for vaccine allocation, prior to the establishment of community transmission. By
21 extending the SEIR model to incorporate a range of vaccine mechanisms and disease characteristics,
22 we study the impact of vaccination on a population comprised of individuals at high and low risk
23 of infection. We then compare the outcomes of optimal and suboptimal vaccination strategies for
24 a range of public health objectives using numerical optimisation. Our comparison shows that the
25 difference between vaccinating optimally and suboptimally is dependent on vaccine mechanism, dis-
26 eases characteristics, and objective considered. Even when sufficient vaccine resources are available,
27 allocation strategy remains important as allocating suboptimally could result in a worse outcome
28 than allocating limited vaccine resources optimally. This work highlights the importance of designing
29 effective vaccine allocation strategies, as allocation of resources can be just as crucial to the success
30 of the overall strategy as total resources available.

31 **1. Introduction.** Pre-epidemic vaccination is an important intervention for managing dis-
32 ease, and when supply is limited vaccines should be used strategically as part of pandemic
33 preparedness. The difference in the outcomes of various allocation strategies will depend on
34 the characteristics of the pathogen and on vaccine mechanisms. Understanding how these
35 characteristics affect both the optimal allocation strategy and the difference in outcomes be-
36 tween strategies is vital when planning vaccine allocation for novel pathogens or pathogen
37 strains.

*Submitted to the editors DATE.

38

39 When new viruses emerge, we aim to design effective vaccination strategies based on knowledge
40 of previous pandemics and emerging information [1, 2]. For example, when vaccinating against
41 influenza, there are benefits to targeting vaccination towards those most vulnerable to disease,
42 and targeting vaccination towards those most likely to spread disease [3, 4]. However, these
43 benefits are highly dependent on disease parameters as well as relative efficacy of the vaccine
44 between population groups [5, 6]. When vaccines are available or potential vaccines are in
45 development for novel pathogens, modelling has been used to develop optimal vaccination
46 strategies [7, 8]. However, any strategy developed must be regularly reevaluated as new virus
47 variants emerge. For example, the emergence of new variants for COVID-19 in 2021, notably
48 the Delta and Omicron variants, have necessitated the reevaluation of current intervention
49 strategies. As more information became available about the characteristics of the Delta and
50 Omicron variants, many countries adapted their vaccination strategies to prioritise booster
51 doses [9, 10], partly due to decreased vaccine effectiveness.

52 Mathematical modelling provides the tools to quantify how vaccine mechanisms and disease
53 characteristics may affect the optimal impact of vaccine allocation. For simple epidemiological
54 models such as the SIR or SEIR model, we can calculate the threshold vaccination needed to
55 ensure $R_0 < 1$ which ensures sustained transmission is not possible. While we can derive the
56 threshold of vaccination to ensure $R_0 < 1$ for more complex models, the relationship between
57 various objectives such as total infections or deaths and R_0 is no longer as simple as before.
58 As such, calculating the number of vaccines needed to optimise a specific objective requires
59 careful thought and potentially numerical methods. Realistically, we may instead compare
60 a range of vaccination strategies to determine which results in the best outcome for a given
61 objective, deeming this the optimal of the strategies considered [3, 7, 8, 11]. In general, the
62 specific public health objective considered impacts results, so we need to consider which model
63 outputs, such as total infections, total symptomatic infections and total deaths, are most ap-
64 propriate to minimise when optimising a vaccine allocation strategy [12].

65

66 Two important areas related to pre-epidemic vaccination are predicting optimal vaccine al-
67 location to prepare for potential pandemics, and designing optimal vaccine allocation strate-
68 gies based on limited information from novel pandemics. To predict the optimal allocation
69 strategy for potential pandemics, we want to know who to vaccinate and when to vaccinate.
70 Vaccines are generally most effective when allocated early in the outbreak and rapidly, focus-
71 ing primarily on vulnerable people and highly transmissible groups [3, 4, 6, 13, 14]. When a
72 pandemic begins, we can apply the findings from this literature to predict effective strategies

73 based on what information is available. For both influenza and COVID-19, optimal vac-
74 cine strategies depend on how transmissibility, severity and vaccine effectiveness vary by age
75 [4, 11, 7, 15, 16, 8]. While these analyses focus on predicting the optimal vaccine allocation
76 strategy, they do not present a generalised understanding of difference between optimal and
77 suboptimal strategies. Are there certain situations where vaccine coverage should be priori-
78 tised, irrespective of who gets vaccinated? Or are there situations where we should ensure
79 every available vaccine is allocated optimally?

80

81 In this paper we determine optimal vaccination strategies for a range of vaccine mechanisms
82 and strategic objectives, and compare the outcomes of optimal and suboptimal strategies.
83 We take a deterministic modelling approach and consider the effects of four separate vaccine
84 mechanisms on a population comprised of people at high and low risk of infection. We deter-
85 mine the optimal allocation strategies for this population for a variety of allocation objectives.
86 Through comparing the outcomes of optimal and suboptimal allocation strategies, we investi-
87 gate how disease characteristics and vaccine characteristics (such as vaccine effectiveness and
88 coverage) impact the differences in outcomes for various strategies. This analysis explores how
89 the benefits of prioritising better vaccine resources over targeted allocation change depending
90 on the scenario considered.

91 **2. Method.** We define a modified SEIR model with two age classes, symptomatic and
92 asymptomatic infection, and death due to disease. We consider vaccine mechanisms that
93 prevent transmission, or symptomatic or severe disease, and consider scenarios where people
94 are vaccinated before an epidemic starts. Through numerical simulation of our model, we aim
95 to minimise either total infections, symptomatic infections or deaths and explore how disease
96 and vaccine characteristics affect the outcome of various vaccine allocation strategies.

97 **2.1. Transmission model.** To model the effects of pre-epidemic vaccination, we extend the
98 SEIR model for two population groups to include vaccination, asymptomatic and symptomatic
99 disease progression, and death due to disease. We define our model from the following disease
100 progression:


- 101 • Each population group is initially split into *unvaccinated* and *vaccinated* susceptibles,
- 102 • If infected, a susceptible person becomes *exposed*, where they are infected but not yet
103 infectious,
- 104 • An exposed person will become *infectious*, developing either symptomatic or asymp-
105 tomatic disease,
- 106 • A person with symptomatic disease can either *recover* from disease, or *die* due to

107 infection,

108 • A person with asymptomatic disease will *recover* from disease.

109 We define an ODE model from these assumptions, as shown in the compartmental diagram
110 in Figure 1.

111



$$\lambda_i = \sum_{j=1}^2 \frac{\beta C_{ij}}{LP_j} (I_{USj} + \delta_A I_{UAj} + \alpha_4 [I_{VSj} + \delta_A I_{VAj}])$$

Figure 1: Compartmental diagram for our extended SEIR model. Initially people are either susceptible (U_i) or vaccinated (V_i) where $i \in \{1, 2\}$ denotes population group. Both classes are able to become exposed (E_{ji}) and then infected (I_{jki}) where $j \in \{U, V\}$ denotes whether they were initially unvaccinated or vaccinated and $k \in \{S, A\}$ denotes if they experience symptomatic or asymptomatic disease. From here, symptomatic people or asymptomatic can recover from disease (R_{jki}) or symptomatic people can also die due to disease (D_{ji}). For each group, ω_i denotes the probability of developing symptomatic infection and σ_i denotes the probability of dying due to disease. We define vaccine effectiveness for each mechanism as $1 - \alpha_m$ for $m \in \{1, 2, 3, 4\}$. We consider mechanisms: 1) reducing susceptibility, 2) reducing probability of developing symptomatic infection, 3) reducing probability of dying due to disease, and 4) reducing infectivity. In the force of infection λ_i , $1 - \delta_A$ denotes the reduction in infectivity due to asymptomatic infection and LP_j denotes the number of people alive in Group j .

112 In our model, we define compartments X_{jki} , where

113 • $X \in \{U, V, E, I, R, D\}$: denotes compartment types; unvaccinated, vaccinated, ex-
114 posed, infected, recovered and dead,

- 115 • $j \in \{U, V\}$: denotes unvaccinated or vaccinated disease progression,
- 116 • $k \in \{S, A\}$: denotes symptomatic or asymptomatic infection, and
- 117 • $i \in \{1, 2\}$: denotes population group (1: high risk of infection, 2: low risk of infection).

118

119 We incorporate the varying risk of infection between population groups by assuming people
120 in Group 1 (high risk) are twice as susceptible to infection than people in Group 2 (low risk).

121 From this assumption, we define a contact matrix C :

$$122 \quad (2.1) \quad C = \begin{matrix} & I_1 & I_2 \\ \begin{matrix} S_1 \\ S_2 \end{matrix} & \begin{bmatrix} 2 & 2 \\ 1 & 1 \end{bmatrix} \end{matrix},$$

123 where Group 1 is high risk and Group 2 is low risk, S denotes the susceptible groups (S_i and
124 V_i) and I denotes the infected groups ($I_{SS_i}, I_{SA_i}, I_{VS_i}$ and I_{VA_i}).

125

126 To investigate the effects of a range of vaccine mechanisms, we consider four vaccine mecha-
127 nisms [16]:

- 128 1. Reduction in susceptibility,
- 129 2. Reduction in probability of developing symptomatic infection,
- 130 3. Reduction in probability of dying due to disease, and
- 131 4. Reduction in infectivity.

132

133 We define the effectiveness of each vaccine as $1 - \alpha_{m \in \{1,2,3,4\}} \in [0, 1]$, corresponds to the vac-
134 cine number as defined above. An 100% effective vaccine ($1 - \alpha_m = 1$) corresponds to a perfect
135 vaccine, for example if $\alpha_1 = 0$, vaccinated individuals are unable to be infected. Conversely,
136 a 0% effective vaccine ($1 - \alpha_m = 0$) corresponds to the vaccine having no effect. As we only
137 consider pre-epidemic vaccination, vaccine allocation appears in the initial conditions for the
138 vaccinated compartments for Groups 1 (high risk) and 2 (low risk).

139

140 In this model, we assume frequency dependent transmission i.e. the transmission rate de-
141 pends on the proportion of infecteds in the population as the contact rate is independent of
142 population size. This is preferred for modelling human populations over density dependent
143 transmission as we determine our contacts by social constraints, which do not necessarily
144 scale with population size [5]. We further assume progress on a fast enough timescale that
145 we can ignore births and natural deaths and that the population is closed. Therefore, total

146 population for each group $P_{i \in \{1,2\}}$ is constant, but this population also includes people who
147 have died due to disease. To implement frequency dependent transmission, we define a new
148 population size $LP_{i \in \{1,2\}}(t)$ which denotes the size of the *living* population for each group.
149 This living population will change over time as people die due to disease. As people die and no
150 longer have contact with living people (we assume), for the same number of infected people,
151 the proportion of infected contacts will increase.

152

153 From the assumptions stated above, we derive the ODEs to describe our model. In addition
154 to the standard SEIR model parameters and the vaccine effectiveness parameters α_m , ω_i de-
155 notes the proportion of exposed individuals that become symptomatically infected, σ_i denotes
156 the proportion of symptomatic individuals who die due to disease, and $1 - \delta_A$ denotes the
157 reduction in infectivity for asymptomatic infecteds, all for a population group i . Furthermore,
158 $[C_{ij}]$ denotes the elements of the contact matrix as defined in Eq. (2.1), P_j denotes the size of
159 Group j at the beginning of the epidemic, and $LP_j(t)$ denotes the size of the living population
160 of Group j . Our model is hence by the following equations for each population group:

161

162

Unvaccinated:

163 (2.2)
$$\frac{dU_i}{dt} = -\lambda_i(t)U_i(t)$$

164 (2.3)
$$\frac{dE_{U_i}}{dt} = \lambda_i(t)U_i(t) - \theta E_{U_i}(t)$$

165 (2.4)
$$\frac{dI_{US_i}}{dt} = \omega_i \theta E_{U_i}(t) - \gamma I_{US_i}(t)$$

166 (2.5)
$$\frac{dI_{UA_i}}{dt} = (1 - \omega_i) \theta E_{U_i}(t) - \gamma I_{UA_i}(t)$$

167 (2.6)
$$\frac{dR_{US_i}}{dt} = (1 - \sigma_i) \gamma I_{US_i}(t)$$

168 (2.7)
$$\frac{dD_{U_i}}{dt} = \sigma_i \gamma I_{US_i}(t)$$

169 (2.8)
$$\frac{dR_{UA_i}}{dt} = \gamma I_{UA_i}(t)$$

170

171

Vaccinated:

$$172 \quad (2.9) \quad \frac{dV_i}{dt} = -\alpha_1 \lambda_i(t) V_i(t)$$

$$173 \quad (2.10) \quad \frac{dE_{Vi}}{dt} = \alpha_1 \lambda_i(t) V_i(t) - \theta E_{Vi}(t)$$

$$174 \quad (2.11) \quad \frac{dI_{VSi}}{dt} = \alpha_2 \omega_i \theta E_{Vi}(t) - \gamma I_{VSi}(t)$$

$$175 \quad (2.12) \quad \frac{dI_{VAi}}{dt} = (1 - \alpha_2 \omega_i) \theta E_{Vi}(t) - \gamma I_{VAi}(t)$$

$$176 \quad (2.13) \quad \frac{dR_{VSi}}{dt} = (1 - \alpha_3 \sigma_i) \gamma I_{VSi}(t)$$

$$177 \quad (2.14) \quad \frac{dD_{Vi}}{dt} = \alpha_3 \sigma_i \gamma I_{VSi}(t)$$

$$178 \quad (2.15) \quad \frac{dR_{VAi}}{dt} = \gamma I_{VAi}(t).$$

180 *Force of infection*

$$181 \quad (2.16) \quad \lambda_i(t) = \sum_{j=1}^2 \beta C_{ij} \frac{I_{USj}(t)}{LP_j(t)} + \delta_A \beta C_{ij} \frac{I_{UAj}(t)}{LP_j(t)} + \alpha_4 \left[\beta C_{ij} \frac{I_{VSj}(t)}{LP_j(t)} + \delta_A \beta C_{ij} \frac{I_{VAj}(t)}{LP_j(t)} \right]$$

$$182 \quad (2.17) \quad \Rightarrow \lambda_i(t) = \sum_{j=1}^2 \frac{\beta C_{ij}}{LP_j(t)} (I_{USj}(t) + \delta_A I_{UAj}(t) + \alpha_4 [I_{VSj}(t) + \delta_A I_{VAj}(t)])$$

184 Adding Eqs. (2.2)–(2.15) we find:

$$185 \quad \sum_{\substack{i \in \{1,2\} \\ j \in \{U,V\} \\ k \in \{S,A\}}} \frac{dU_i}{dt} + \frac{dV_i}{dt} + \frac{dE_{ji}}{dt} + \frac{dI_{jki}}{dt} + \frac{dR_{jki}}{dt} + \frac{dD_{ji}}{dt} = 0$$

$$186 \quad \Rightarrow \sum_{\substack{i \in \{1,2\} \\ j \in \{U,V\} \\ k \in \{S,A\}}} U_i(t) + V_i(t) + E_{ji}(t) + I_{jki}(t) + R_{jki}(t) + D_{ji}(t) = \sum_{i \in \{1,2\}} P_i,$$

188 where we define P_1 and P_2 as the population sizes of Groups 1 and 2 at the beginning of the
 189 epidemic. For our analysis we assume $P_1 = P_2$. As the epidemic progresses and people die
 190 due to disease, we define the living population size $LP_{i \in \{1,2\}}(t)$ as:

$$191 \quad LP_i(t) = P_i - D_{U_i}(t) - D_{V_i}(t).$$

192 Given both Groups 1 and 2 start with I_0 infections each, and v_1 and v_2 vaccinations respec-

193 tively, Eqns (2.2)–(2.15) have the following initial conditions:

194
$$U_i(0) = P_i - v_i - I_0$$

195
$$V_i(0) = v_i$$

196
$$E_{ji}(0) = 0$$

197
$$I_{Uki}(0) = \frac{1}{2}I_0$$

198
$$I_{Vki}(0) = 0$$

199
$$R_{jki}(0) = 0$$

200
$$D_{ji}(0) = 0,$$

202 for $i \in \{1, 2\}$, $j \in \{U, V\}$ and $k \in \{S, A\}$. That is, we assume there are initially $2I_0$ infected
203 people with I_0 infected people in each population group. For each population group all initially
204 infected people are unvaccinated with half symptomatic and the other half asymptomatic,
205 which is why $I_{Uki}(0)$ is equal to $\frac{1}{2}I_0$ for $k \in \{S, A\}$. In our analysis we assume $I_0 = 50$.
206 Complete modelling details are given in the supplementary material.

207 **2.2. Optimising Vaccine Allocation.** To find the optimal vaccine allocation strategy, we
208 compute the number of vaccines allocated to each population group to minimise a given
209 objective function. Given we consider a finite number of vaccines (v_{max}) and two population
210 groups, the problem reduces to finding the number of vaccines to allocate to Group 1 (v_{opt})
211 to minimise the objective function:

212 (2.18)
$$v_{opt} = \min_{v \in \{1, \dots, v_{max}\}} \{\text{objective function}(y(v))\},$$

213 where y is the output from the model Eqs. (2.2)–(2.15) with initial conditions $V_1(0) = v$ and
214 $V_2(0) = v_{max} - v$.

215

216 The three objective functions that we consider are:

217 1. Total infections:

218
$$\sum_{\substack{i \in \{1, 2\} \\ j \in \{U, V\} \\ k \in \{S, A\}}} R_{jki}(\infty) + D_{ji}(\infty)$$

219 2. Total symptomatic infections:

220
$$\sum_{\substack{i \in \{1,2\} \\ j \in \{U,V\}}} R_{jsi}(\infty) + D_{ji}(\infty)$$

221 3. Total deaths:

222
$$\sum_{\substack{i \in \{1,2\} \\ j \in \{U,V\}}} D_{ji}(\infty)$$

223 where $X(\infty) := \lim_{t \rightarrow \infty} X(t)$ denotes the size of compartment X at the end of the epidemic.

224

225 We aim to compare optimal and suboptimal strategies for discrete and continuous variables.

226 For discrete variables, we will compare the outcomes of a variety of strategies generated by

227 allocating all vaccines in varying proportions to each group. For continuous variables, we will

228 compare the outcome of the optimal strategy with the outcomes of vaccinating each group

229 equally (an uninformed strategy) and vaccinating poorly. We calculate the poor strategy by

230 comparing the outcome of a variety of strategies and selecting the worst. For example, if the

231 optimal strategy prioritises vaccinating for Group 1 (high risk) and a poor strategy was found

232 to prioritise vaccinating for Group 2 (low risk), our three comparison strategies are:

233 1. Optimal strategy: prioritise vaccinating Group 1,

234 2. Uninformed strategy: vaccinate Groups 1 and 2 equally,

235 3. Poor strategy: prioritise vaccinating Group 2.

236

237 The results presented here were generated using MATLAB 9.10. The model was simulated

238 using `ode45` and as the optimisation problem reduces to one dimension, the optimal strategy

239 was computed using `fmincon`.

240 **3. Results.** We present our results through the following analysis:

241 1. How do disease characteristics lead to variation in the differences in outcomes between
242 optimal and suboptimal vaccination strategies?

243 2. How does the difference in outcome between optimal and suboptimal strategies depend
244 on vaccine effectiveness and coverage?

245 When examining our results, it is useful to think about the direct and indirect effects of var-

246 ious parameters or vaccine mechanisms. We use “direct effects” to mean mechanisms that

247 impact only vaccinated individuals, for example if the vaccine reduces the probability of hos-

248 pitalisation. Conversely, we use “indirect effects” to refer to mechanisms that both vaccinated


249 and unvaccinated individuals, for example if a vaccine results in reduced transmission.
250 In the following sections we provide a subset of model results, which explore interest aspects
251 of our model. However, we also provide a complete set of model results in the supplementary
252 material.

253 **3.1. Varying disease characteristics.** Here we present results that consider how the dif-
254 ference between optimal and suboptimal strategies is dependent on disease characteristics for
255 various vaccine mechanisms and allocation objectives. We consider vaccination strategies for
256 a 75% effective vaccine with 50% vaccine coverage. These values have been chosen arbitrar-
257 ily to demonstrate the effects of varying disease characteristics. As we assume Group 1 and
258 Group 2 are the same size, 50% vaccine coverage provides interesting results as it gives us the
259 potential to vaccinate the entirety of one population group. Furthermore, we are interested
260 in relatively effective vaccines, but still want to capture their imperfection and so we choose
261 an effectiveness of 75%. Unless otherwise stated, we assume a total population of size of
262 $N = 10000$, with 5000 people in each group ($P_1 = P_2 = 5000$).

263
264 The plots in Figure 2 show the effects of varying a parameter that affects transmission (R_0)
265 and another that affects infection characteristics (σ) on the difference between optimal and
266 suboptimal allocation strategies.

267
268 We consider the effect of varying R_0 on the difference in outcomes between strategies as shown
269 in Figure 2a. Mathematically, there are two points of interest in this figure, the initial con-
270 vexity of all the strategies and the point where the outcomes of the strategies meet. For low
271 R_0 , we see convex curves for each of the considered strategies due to the infection curves
272 being dominated by the decay of initially infected people, rather than new infections. As R_0
273 increases, we recover the shape of a standard final size curve as our epidemic takes off (in spite
274 of vaccination). Our second point of interest is where the outcomes of the three considered
275 strategies meet, where we define $R_0 = R'_0 \approx 2.5$. For $R_0 < R'_0$, the optimal strategy is to vac-
276 cinate Group 1 and the poor strategy is to vaccinate Group 2. For $R_0 > R'_0$ we find that the
277 optimal strategy is to vaccinate Group 2 and the poor strategy is to vaccinate Group 1. Hence, as
278 we approach $R_0 = R'_0$, our optimal and poor strategies approach one another before swapping.

279
280 Qualitatively, we see a difference in outcome for all strategies as we vary R_0 . While the dif-
281 ference in outcome for high and low R_0 depends on the strategy we choose, for all strategies
282 total infections are monotonically increasing with R_0 . The importance of choosing the opti-
283 mal strategy also varies with R_0 , with the largest differences between the optimal and poor



(a) Total infections for a vaccine that reduces susceptibility by 75% with 50% coverage for three allocation strategies as we continuously vary R_0 .

(b) Total deaths for a vaccine that reduces the probability of severe disease by 75% with 50% coverage for a range of allocation strategies as we vary the probability of dying due to infection (σ_i) for each population group.

Figure 2: Comparing the differences between strategies for varying vaccine mechanisms and allocation objectives as we vary R_0 and σ_i .

284 strategies being when R_0 is between 1 and 2. While as R_0 increases above 5, the outcome for
 285 all strategies gets consistently worse and the difference between strategies decreases.

286 Figure 2b shows how differences in outcomes between strategies change as we vary the prob-
 287 ability of dying due to infection for each population group ($\sigma_{i \in \{1,2\}}$). We consider three
 288 scenarios σ_i : $\sigma_1 > \sigma_2$, $\sigma_1 = \sigma_2$, and $\sigma_1 < \sigma_2$. The biggest difference in outcomes of strategies
 289 happens when $\sigma_1 \neq \sigma_2$. When $\sigma_1 = \sigma_2$, the only factor influencing the difference in deaths
 290 between population groups is their relative susceptibility (as defined previously). Hence, while
 291 there is a difference in the number of people infected in each population group, vaccination
 292 will reduce the probability of dying due to disease to the same value for each group. However,
 293 when $\sigma_1 \neq \sigma_2$, one group will be more likely to die due to disease. Therefore, vaccinating the
 294 group more likely to die due to disease will reduce more deaths than vaccinating the other
 295 group, widening the gap between the outcomes of various strategies. For parameters with only
 296 direct effects, such as σ_i , vaccination only affects vaccinated people. The difference between
 297 outcomes of allocation strategies is therefore dependent on how the parameters for each group
 298 compare to one another.

299

300 The two examples presented in Figure 2 demonstrate how direct and indirect affects of vac-

301 cination impact the differences in outcomes between optimal and suboptimal strategies. For
302 parameters affecting transmission (e.g. R_0) the difference between outcomes of strategies is
303 dependent on the value of the parameter itself. This is due to its affect on transmission
304 for both population groups. However, for parameters affecting individual infection (e.g. σ_i)
305 the difference between outcomes of strategies is dependent on the relative parameter values
306 between each population group. The biggest differences between outcomes of strategies will
307 occur with there is large disparity in the parameter between groups, and the smallest difference
308 when both groups are equal.

309 **3.2. Varying vaccine characteristics.** We now consider an example population to demon-
310 strate how vaccine effectiveness and coverage affect the differences in outcomes between alloca-
311 tion strategies. We define Group 1 to be more susceptible, more likely to develop symptomatic
312 disease and more likely to die due to disease, and Group 2 to be less susceptible, less likely to
313 develop symptomatic disease and less likely to die due to disease.

314


315 Figure 3 compares the differences between allocation strategies for various vaccine mechanisms
316 and allocation objectives as we vary vaccine effectiveness and coverage.

317

318 Figures 3a and 3b show the total infections for vaccines that affect transmission as vaccine
319 effectiveness and coverage are varied. For the considered parameters, the optimal strategy
320 changes from prioritising vaccination for Group 2 to prioritising vaccination for Group 1 at
321 63% effectiveness (3a). For both vaccine effectiveness and coverage, as we saw in Figure 2a, as
322 we increase our vaccine parameter we reduce our objective for all allocation strategies. As the
323 vaccine tends towards becoming 100% effective, or there is high coverage (80%), the optimal
324 strategy produces a much better result than other strategies. However, for lower effectiveness
325 and coverage, increasing the either parameter decreases our objective for all strategies. This
326 demonstrates that, in our model, securing better vaccines or more vaccines will work to de-
327 crease our objective, even under a suboptimal strategy.

328

329 Figures 3c and 3d show how total symptomatic infections and total deaths for vaccines that
330 affect individual infection vary and we change vaccine effectiveness and coverage. In Figure
331 3d the difference between optimal and suboptimal strategies is much smaller for 20% and 80%
332 coverage than 50% as there are fewer ways to allocate vaccines for 20% and 80% coverage than
333 for 50% coverage. As vaccine effectiveness and coverage increase, there is a large reduction
334 in outcome for optimal (and close to optimal) strategies, but a much smaller improvement
335 for poor strategies. As vaccination only impacts infected people, vaccinating the less vul-



(a) Total infections for a vaccine that reduces susceptibility for three allocation strategies as we vary vaccine effectiveness.

(b) Total infections for a vaccine that reduces infectivity for a range of allocation strategies as we vary vaccine coverage. Note the change in axis scale due to limited effect from a vaccine that reduces infectivity.

(c) Total symptomatic infections for a vaccine that reduces the probability of developing symptomatic infection for three allocation strategies as we vary vaccine effectiveness.

(d) Total deaths for a vaccine that reduces the infection fatality rate for a range of allocation strategies as we vary vaccine coverage.

Figure 3: Comparing the differences between strategies for varying vaccine mechanisms and allocation objectives as we vary vaccine effectiveness and coverage.

336 nerable, who are already unlikely to experience symptomatic or severe disease, does little
 337 to reduce an objective focused on these infection characteristics. Unlike a vaccine affecting
 338 transmission, where increasing quality or quantity of vaccines works to decrease the objective
 339 for all strategies, here there is only a sizeable reduction for the best strategies. This indicates
 340 that strategy remains important even when effective vaccines and high coverage is available.

341 For our model, allocating poorly with an effective vaccine or high coverage could result in a
342 much worse outcome than allocating well with an ineffective vaccine or lower vaccine coverage.

343

344 For our model and the parameters we chose, the difference between optimal and suboptimal
345 strategies varies as we change vaccine effectiveness and coverage based on both vaccine mech-
346 anism and allocation objective. If a vaccine mechanism affects transmission, this will impact
347 the total number of infections, and therefore also the total symptomatic infections and total
348 deaths resulting from these infections. Hence for any of these objectives, increasing vaccine
349 effectiveness or coverage will result in a better outcome for all strategies. However, if a vaccine
350 mechanism only results in direct effects, this will only impact objectives associated with the
351 mechanism. For example, a vaccine that reduces the probability of dying due to disease will
352 have no impact on total infections or total symptomatic infections. When the vaccine mecha-
353 nism does impact an objective, increasing vaccine effectiveness and coverage is only effective
354 when an optimal, or close to optimal, strategy is employed.

355 **4. Discussion.** Our results demonstrate that the difference between outcomes of vaccine
356 allocation strategies depends on both disease and vaccine characteristics. The difference in
357 outcomes between strategies is dependent on whether a considered parameter directly or in-
358 directly impacts the outcome. For the former the difference between strategies is dependent
359 heavily on the parameter value itself, whereas for the latter the difference is dependent on
360 the relative values of the parameter between population groups. Furthermore, a vaccine with
361 direct effects will only impact vaccinated people, and so in our model poor vaccine resources
362 allocated well can result in a better outcome than good vaccine resources allocated poorly.
363 Conversely, if vaccination indirectly effects the outcome, better vaccine resources will result
364 in a better outcome for all strategies. These findings emphasise the importance of identifying
365 the direct and indirect effects of vaccination when determining allocation strategy.

366

367 By investigating allocation strategies for individual vaccine mechanisms and objectives, we
368 lay foundations for a model that considers multi-mechanism or multi-objective strategies.
369 When designing vaccine strategies with little knowledge about the specifics of the vaccine,
370 modelling often assumes individual mechanisms, or simply a vaccine that provides protection
371 [7, 15, 16]. When vaccines eventually become available and are observed to include multiple
372 mechanisms, these mechanisms are built into models through using effectiveness parameters
373 from data [17, 18, 19]. Our model incorporates multiple possible vaccine mechanisms, however
374 we restrict our analysis to the impact of each separately.

375

376 Furthermore, in this paper we have considered objectives that are not strictly independent
377 of one another. Due to our model assumptions, reducing infections leads to a reduction in
378 symptomatic infections which further leads to a reduction in deaths. However, by consider-
379 ing the impacts of vaccination on transmission or individual infection, we can determine the
380 impact of various disease and vaccine characteristics on the outcome of independent objec-
381 tives. To consider allocation strategies for multiple objectives would require development of
382 a single objective through weighting individual objectives based on importance. The impact
383 of vaccination on this overarching objective could then be thought of in terms of the impact
384 of vaccination on each individual part, as described in our results.

385 While our model is sufficient to start learning about the importance of different vaccine mecha-
386 nisms, it may not describe specific, realistic scenarios. In our model, we assume SEIR dynamics
387 and divide the population into people with high and low risk to infection. To model a more
388 realistic scenario, we would likely need to extend our model to capture a more complex pop-
389 ulation and transmission structure. In particular, we assumed constant vaccine effectiveness
390 across our population, but age dependent vaccine effectiveness has been observed, for example
391 for influenza vaccines [20]. When considered in the model, this could alter not only the op-
392 timal vaccination strategy, but also the difference between optimal and suboptimal strategies
393 [3, 16, 21]. While the simplicity of our model allows us to analyse the differences in outcomes
394 between optimal and suboptimal strategies, more information and a model incorporating ob-
395 served heterogeneities are needed to produce results for a realistic vaccination scenario.

396

397 By investigating how various factors impact the outcomes of vaccination strategies in our
398 model, we explore the idea of prioritising vaccine allocation over ascertainment. When new
399 scenarios arise, such as new vaccines available or new variants appearing, our results allows
400 us to compare how allocation strategies differ in this new scenario compared to an old sce-
401 nario. Is it still worth sourcing more vaccines with the current allocation strategy or will
402 increased coverage only improve the outcome if we vaccinate more effectively? How great are
403 the benefits from allocating vaccines optimally now that our vaccine is less effective against
404 a new variant? Do suboptimal strategies perform similarly? Our results show that investi-
405 gating how individual disease and vaccine characteristics impact the difference in outcomes
406 between vaccination strategies allows the reassessment of vaccine allocation as information on
407 an emerging disease becomes available and reinforces the need to carefully consider allocation
408 strategy when distributing vaccines.

409

410 **Code availability.** The MATLAB code used to generate all results in this manuscript is
411 available online https://github.com/iabell/vaccine_allocation.

412 **Supplementary materials.** Additional figures and model details can be found in the sup-
413 plementary materials.

414 REFERENCES

- 415 [1] Australian health management plan for pandemic influenza. Technical report, Australian Government
416 Department of Health, 2019.
- 417 [2] Brian J Coburn, Bradley G Wagner, and Sally Blower. Modeling influenza epidemics and pandemics:
418 insights into the future of swine flu (H1N1). *BMC Medicine*, 7(1):30, December 2009.
- 419 [3] Jonathan Dushoff, Joshua B Plotkin, Cecile Viboud, Lone Simonsen, Mark Miller, Mark Loeb, and David
420 J. D Earn. Vaccinating to Protect a Vulnerable Subpopulation. *PLoS Medicine*, 4(5):e174, May 2007.
- 421 [4] C. Degeling, J. Williams, S.M. Carter, R. Moss, P. Massey, G.L. Gilbert, P. Shih, A. Braunack-Mayer,
422 K. Crooks, D. Brown, and J. McVernon. Priority allocation of pandemic influenza vaccines in Australia
423 – Recommendations of 3 community juries. *Vaccine*, 39(2):255–262, January 2021.
- 424 [5] Matthew James Keeling and Pejman Rohani. *Modeling infectious diseases in humans and animals*. Prince-
425 ton University Press, Princeton, 2008. OCLC: ocn163616681.
- 426 [6] Matt J. Keeling and Peter J. White. Targeting vaccination against novel infections: risk, age and spatial
427 structure for pandemic influenza in Great Britain. *Journal of The Royal Society Interface*, 8(58):661–
428 670, May 2011. Publisher: Royal Society.
- 429 [7] Eunha Shim. Optimal Allocation of the Limited COVID-19 Vaccine Supply in South Korea. *Journal of*
430 *Clinical Medicine*, 10(4):591, February 2021.
- 431 [8] Brody H. Foy, Brian Wahl, Kayur Mehta, Anita Shet, Gautam I. Menon, and Carl Britto. Comparing
432 COVID-19 vaccine allocation strategies in India: A mathematical modelling study. *International*
433 *journal of infectious diseases: IJID: official publication of the International Society for Infectious*
434 *Diseases*, 103:431–438, February 2021.
- 435 [9] Georgina Kenyon. Australia’s struggle with the delta variant. *The Lancet Infectious Diseases*, 21(10):1358,
436 October 2021. Publisher: Elsevier.
- 437 [10] Elie Dolgin. Omicron is supercharging the COVID vaccine booster debate. *Nature*, December 2021.
438 Bandiera_abtest: a Cg_type: News Publisher: Nature Publishing Group Subject_term: SARS-CoV-2,
439 Virology, Immunology, Public health, Vaccines.
- 440 [11] Sunmi Lee, Michael Golinski, and Gerardo Chowell. Modeling Optimal Age-Specific Vaccination Strate-
441 gies Against Pandemic Influenza. *Bulletin of Mathematical Biology*, 74(4):958–980, April 2012.
- 442 [12] William J. M. Probert, Katriona Shea, Christopher J. Fonnesbeck, Michael C. Runge, Tim E. Carpen-
443 ter, Salome Dürr, M. Graeme Garner, Neil Harvey, Mark A. Stevenson, Colleen T. Webb, Marleen
444 Werkman, Michael J. Tildesley, and Matthew J. Ferrari. Decision-making for foot-and-mouth disease
445 control: Objectives matter. *Epidemics*, 15:10–19, June 2016.
- 446 [13] Mingmei Teo, Nigel Bean, and Joshua V. Ross. Optimised prophylactic vaccination in metapopulations.
447 *Epidemics*, 34:100420, March 2021.
- 448 [14] Jan Medlock and Alison P. Galvani. Optimizing Influenza Vaccine Distribution. *Science*, 325(5948):1705–
449 1708, September 2009. Publisher: American Association for the Advancement of Science.

-
- 450 [15] Laura Matrajt, Julia Eaton, Tiffany Leung, and Elizabeth R. Brown. Vaccine optimization for COVID-19:
451 Who to vaccinate first? *Science Advances*, 7(6):eabf1374, February 2021.
- 452 [16] Sam Moore, Edward M. Hill, Louise Dyson, Michael J. Tildesley, and Matt J. Keeling. Modelling optimal
453 vaccination strategy for SARS-CoV-2 in the UK. *PLOS Computational Biology*, 17(5):e1008849, May
454 2021. Publisher: Public Library of Science.
- 455 [17] Laura Matrajt, Julia Eaton, Tiffany Leung, Dobromir Dimitrov, Joshua T. Schiffer, David A. Swan, and
456 Holly Janes. Optimizing vaccine allocation for COVID-19 vaccines shows the potential role of single-
457 dose vaccination. *Nature Communications*, 12(1):3449, June 2021. Number: 1 Publisher: Nature
458 Publishing Group.
- 459 [18] Nicholas Steyn, Michael J. Plank, Rachelle N. Binny, Shaun C. Hendy, Audrey Lustig, and Kannan
460 Ridings. A COVID-19 vaccination model for Aotearoa New Zealand. *Scientific Reports*, 12(1):2720,
461 February 2022. Number: 1 Publisher: Nature Publishing Group.
- 462 [19] Jodie McVernon, David J Price, Patricia T. Campbell, Nick Golding, Christopher M. Baker, James
463 Walker, Nic Geard, Freya M Shearer, Eamon Conway, Michael Lydeamore, James Wood, Nic Rebuli,
464 and Joel Miller. Doherty Institute Modelling Report for National Cabinet. Technical report, Doherty
465 Institute, March 2021.
- 466 [20] Katherine Goodwin, Cécile Viboud, and Lone Simonsen. Antibody response to influenza vaccination in
467 the elderly: A quantitative review. *Vaccine*, 24(8):1159–1169, February 2006.
- 468 [21] Ashleigh R. Tuite, David N. Fisman, Jeffrey C. Kwong, and Amy L. Greer. Optimal Pandemic Influenza
469 Vaccine Allocation Strategies for the Canadian Population. *PLoS ONE*, 5(5):e10520, May 2010.